Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 42 min ago
Peer-reviewedCC BY 4.0Frontiers in Endocrinology

Who is to do it? Actor specification in eight society statements on perioperative GLP-1 receptor agonists: a narrative review

  1. 1Department of Anaesthesiology and Perioperative Medicine I, Shandong Provincial Hospital Affiliated to Shandong First Medical University

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists delay gastric emptying, and since June 2023 at least eight society statements have addressed their management before elective surgery and endoscopy. The statements agree on less than is often assumed: they differ on whether to withhold the drug, on whether and how far to lengthen the fast from solids, on whether gastrointestinal symptoms can stratify aspiration risk, and on whether cancellation is a safeguard or a failure. This review asks a question the resulting debate has largely left aside: for each recommendation these statements issue, who is to carry it out? We read the statements against six domains of care they themselves create — medication-history taking, counselling on discontinuation, communication and verification of fasting, metabolic safety during a prolonged liquid-only period, day-of-procedure symptom screening and the gastric-ultrasound pathway, and escalation around cancellation — and recorded how specifically the acting party was identified. Across the eight statements, all ultimately read in full, no recommendation names an accountable role together with a timing and a record; where a professional role is named at all, it is as a party to a referral, a consultation or a decision — the prescribing physician, an endocrinologist, the surgical team — never as the executor of a preparatory task with a timing and a record. The most consequential case is metabolic: four statements replace solid food with a liquid-only period of twenty-four hours or longer whilst advising that glucose-lowering therapy continue. Three of the four are silent on glycaemia, hydration and co-prescribed glucose-lowering drugs during that period; the fourth addresses them — outside its graded recommendations, in the agentless voice, with no role, timing or record — and the remaining operational content in the set sits in the two documents that do not lengthen the fast. We argue that this is a reporting problem as much as a clinical one, that established appraisal instruments already name what is missing, and that the next statement in this sequence should specify, for each recommendation, an accountable role, a timing and a minimum record.

Related

  1. GLP-1 receptor agonists in elective spine surgery: a systematic review of fusion outcomes, perioperative safety, and procedure-specific risk
    Vinicius Ricieri Ferraz, Bashar Dawoud, Philippe A. Mercier +1
    North American Spine Society journalPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMC
  2. Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review
    Audrey Y. Chang, Farrah J. Mateen
    Annals of clinical and translational neurologyPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Perioperative management of GLP-1 receptor agonists and SGLT2 inhibitors: An updated review for anesthesiologists.
    Amer Majeed, Rida R Amir, Sajjad Rasool Dar +1
    Saudi journal of anaesthesiaPeer-reviewedCC BY-NC-SAFull textEndocrinology & metabolismEurope PMCPMC
  4. Glucagon-like peptide-1 receptor agonists and aesthetic surgery: perioperative safety, timing, durability and body composition.
    Richa Chaturvedi, Kuldeep Singh, Rameshwari R Chakole +3
    Frontiers in endocrinologyPeer-reviewedCC BYFull textEndocrinology & metabolismEurope PMCCrossref
  5. Perioperative management of patients taking GLP-1 receptor agonists: A comparative review of international clinical guidelines.
    Thomas Moore, Benjamin Ramsahoye
    Saudi journal of anaesthesiaPeer-reviewedCC BY-NC-SAFull textSurgery & anaesthesiaEurope PMCPMC
BibTeX
@article{wei2026actor,
  title = {{Who is to do it? Actor specification in eight society statements on perioperative GLP-1 receptor agonists: a narrative review}},
  author = {Juanjuan Wei and Qian Li},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  month = nov,
  doi = {10.3389/fendo.2026.1986733},
  url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1986733/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Who is to do it? Actor specification in eight society statements on perioperative GLP-1 receptor agonists: a narrative review
AU  - Juanjuan Wei
AU  - Qian Li
PY  - 2026
DA  - 2026/11/16
JO  - Frontiers in Endocrinology
DO  - 10.3389/fendo.2026.1986733
UR  - https://www.frontiersin.org/articles/10.3389/fendo.2026.1986733/full
AB  - Glucagon-like peptide-1 (GLP-1) receptor agonists delay gastric emptying, and since June 2023 at least eight society statements have addressed their management before elective surgery and endoscopy. The statements agree on less than is often assumed: they differ on whether to withhold the drug, on whether and how far to lengthen the fast from solids, on whether gastrointestinal symptoms can stratify aspiration risk, and on whether cancellation is a safeguard or a failure. This review asks a question the resulting debate has largely left aside: for each recommendation these statements issue, who is to carry it out? We read the statements against six domains of care they themselves create — medication-history taking, counselling on discontinuation, communication and verification of fasting, metabolic safety during a prolonged liquid-only period, day-of-procedure symptom screening and the gastric-ultrasound pathway, and escalation around cancellation — and recorded how specifically the acting party was identified. Across the eight statements, all ultimately read in full, no recommendation names an accountable role together with a timing and a record; where a professional role is named at all, it is as a party to a referral, a consultation or a decision — the prescribing physician, an endocrinologist, the surgical team — never as the executor of a preparatory task with a timing and a record. The most consequential case is metabolic: four statements replace solid food with a liquid-only period of twenty-four hours or longer whilst advising that glucose-lowering therapy continue. Three of the four are silent on glycaemia, hydration and co-prescribed glucose-lowering drugs during that period; the fourth addresses them — outside its graded recommendations, in the agentless voice, with no role, timing or record — and the remaining operational content in the set sits in the two documents that do not lengthen the fast. We argue that this is a reporting problem as much as a clinical one, that established appraisal instruments already name what is missing, and that the next statement in this sequence should specify, for each recommendation, an accountable role, a timing and a minimum record.
SN  - 1664-2392
ER  -